Homepage Top Section1

Keytruda has been approved to treat patients with BCG- unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumours who are ineligible for or have

As per the supplemental New Drug Application (sNDA), AstraZeneca is seeking approval for Farxiga for its use in lowering the risk of cardiovascular (CV) death or the worsening

BeiGene is a commercial-stage oncology firm focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Former Amgen global commercial operations executive vice president

As part of the collaboration and licence agreement, the companies will work together to detect small molecules designed to modulate specific pathways linked with a targeted indication within

Padcev, a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4 protein, has secured approval under the FDA’s Accelerated Approval Program based on tumour response rate. Nectin-4, which

The latest approval means that XTANDI is indicated for the treatment of three distinct forms of advanced prostate cancer that include non-metastatic and metastatic castration-resistant prostate cancer (CRPC),

The two phase 3 trials for Jardiance called EMPERIAL-Reduced and EMPERIAL-Preserved were carried out in adults with chronic heart failure with reduced and preserved ejection fraction, respectively. In

The overall adverse event rate was comparable between tralokinumab and placebo during the trials, said the company. Tralokinumab is an investigational and fully human monoclonal antibody, which neutralises

According to XBiotech, bermekimab has been designed to neutralise interleukin-1 alpha (IL-1⍺), which is known for promoting disease-causing inflammation in a wide variety of medical conditions. As per